Apomorphine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
Alosetron
Antiemetic · Agent for Irritable Bowel Syndrome
Also known as LOTRONEX
AntiemeticAgent for Irritable Bowel SyndromeATC A07DA04
CDSCO approvedSchedule HATC A07DA04
EXCRETION
—
not curated
INTERACTIONS
2 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactions
- ApomorphineSevereDatabaseDDInter
- FluvoxamineSevereDatabaseDDInter
Mechanism
Alosetron is a selective 5-HT3 receptor antagonist. Its mechanism of action involves blocking these receptors, which are implicated in various gastrointestinal disturbances, leading to its efficacy in irritable bowel syndrome.
Indications
Irritable bowel syndromeInflammatory bowel syndrome (especially in women with diarrhea as the principal symptom)Severe diarrhea-predominant IBS (in women, under limited distribution system due to safety concerns)
Dosing
- Adult
- however, with doses of risperidone in excess of 6 mg/day.
Pharmacokinetics
Half-life
1.5 h
Bioavailability
57 (33–97)%
Protein binding
82%
Metabolism
Metabolized by CYP1A2
Excretion
In urine and feces
Side effects
Common
NauseaVomitingGI discomfort and painDiarrheaFlatulenceHemorrhoids
Serious
- Constipation
- Ischemic colitis (unusually high incidence, leading to surgery and death in some cases)
Drug interactions
Fluvoxamine
Severe
Database
alosetron AUC increased 6.0-fold.
coadministration generally contraindicate[d] or at least require[s] dosage adjustment.
Source: DDInter
10 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Related guidelines
Irritable bowel syndrome
ISG · Gastroenterology · 2023
Inflammatory bowel disease
OTHER · Gastroenterology · 2015
Preventive care in inflammatory bowel disease
ACG · Gastroenterology · 2025
Empirical antimicrobial use in common syndromes
ICMR · Infectious Diseases · 2019
Acute coronary syndrome in chronic kidney disease
CSI · Cardiology · 2020
Other Antiemetic drugs
Ask House about Alosetron
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team